BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12829227)

  • 1. [International Congress of the American Society of Hematology, Philadelphia, 6-10 December 2002].
    Veyssier-Belot C;
    Rev Med Interne; 2003 Jul; 24(7):485-90. PubMed ID: 12829227
    [No Abstract]   [Full Text] [Related]  

  • 2. A summer of hematologic science. Highlights from the 45th Annual Meeting of the American Society of Clinical Oncology, the 14th Congress of the European Hematology Association, and the 2009 Pan Pacific Lymphoma Conference.
    Cheson BD; Ashforth E
    Clin Adv Hematol Oncol; 2009 Sep; 7(9 Suppl 15):1-22; quiz 23-4. PubMed ID: 20102012
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent advances in hematology: an update from the 16th Congress of the EHA.
    O'Neill T
    Expert Rev Hematol; 2011 Dec; 4(6):587-9. PubMed ID: 22077521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Five breakthroughs for hematology].
    Palmblad J
    Lakartidningen; 2000 Feb; 97(5):472-3. PubMed ID: 10707500
    [No Abstract]   [Full Text] [Related]  

  • 5. Research in the heart of hematology: chronic myeloid leukemia 2017.
    Hehlmann R
    Haematologica; 2017 Mar; 102(3):418-421. PubMed ID: 28250004
    [No Abstract]   [Full Text] [Related]  

  • 6. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome.
    Alimena G; Breccia M; Mancini M; Ferranti G; De Felice L; Gallucci C; Mandelli F
    Leukemia; 2004 Feb; 18(2):361-2. PubMed ID: 14614517
    [No Abstract]   [Full Text] [Related]  

  • 8. [48th World Congress of the American Society of Hematology].
    L'Allemain G;
    Bull Cancer; 2007 May; 94(5):489-94. PubMed ID: 17535788
    [No Abstract]   [Full Text] [Related]  

  • 9. Hematology: the red science.
    Vincent PC
    Pathology; 1993 Jan; 25(1):39-47. PubMed ID: 8316497
    [No Abstract]   [Full Text] [Related]  

  • 10. Innovation in hematology. Perspectives: CML 2016.
    Hehlmann R
    Haematologica; 2016 Jun; 101(6):657-9. PubMed ID: 27252510
    [No Abstract]   [Full Text] [Related]  

  • 11. Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Beran M
    Leuk Res; 2004 May; 28(5):443-6. PubMed ID: 15068895
    [No Abstract]   [Full Text] [Related]  

  • 12. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.
    Chee YL; Vickers MA; Stevenson D; Holyoake TL; Culligan DJ
    Leukemia; 2003 Mar; 17(3):634-5. PubMed ID: 12646955
    [No Abstract]   [Full Text] [Related]  

  • 13. Philadelphia chromosome positive myelodysplastic syndrome and acute myelogenous leukemia.
    Advani AS
    Leuk Res; 2004 Jun; 28(6):545-6. PubMed ID: 15120928
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
    Radojkovic M; Ristic S; Pavlovic S; Colovic M
    Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of myelodysplastic syndrome in a patient with chronic myelogenous leukemia treated with imatinib.
    Mallik N; Chopra A; Jha A; Gogia A; Kumar R
    Leuk Lymphoma; 2015 Apr; 56(4):1143-4. PubMed ID: 25093381
    [No Abstract]   [Full Text] [Related]  

  • 16. Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.
    Mozziconacci MJ; Caillères S; Maurice C; Vey N; Sainty D; Blaise D; Lafage-Pochitaloff M
    Leukemia; 2003 Sep; 17(9):1901-2. PubMed ID: 12970792
    [No Abstract]   [Full Text] [Related]  

  • 17. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
    J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Differential diagnosis of chronic myeloid leukemia and the related disorders].
    Ashida T; Kanamaru A
    Nihon Rinsho; 2001 Dec; 59(12):2358-62. PubMed ID: 11766339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells.
    Ostro D; Cheung K; Kamel-Reid S; Lipton JH
    Leuk Lymphoma; 2007 May; 48(5):1029-31. PubMed ID: 17487749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.